NEO: Designed to Reassure Born from the will to assist and reassure brands and consumers, Aptar is proud to announce it

Flexible shaft manufacturer provides custom design expertise St. Petersburg, FL – S.S. White Technologies, the worldwide leader in the design and manufacture of flexible shafts, highlights their bespoke flexible shaft solutions for food industry applications. Flexible shafts transmit rotary motion much like a solid shaft, but can be curved over, under, and around areas in ways a solid shaft cannot. Flexible shafts are used in a variety of food applications, such as in rotary knives, mixers, commercial kitchen equipment controls, and in industrial food packaging. S.S. White provides customers with custom flexible shaft solutions designed for individual applications, all backed by S.S. White’s wealth of experience and expertise. Food industry applications suitable for using S.S. White Flexible Shafts include: Rotary knives for the beef, pork, and poultry industry Rotary knives and de-boners for the fish industry Rotary knives to trim meet in taco- and kebab-style restaurants Industrial fryers Mixers Various remote controls for kitchen equipment Coffee machines, for grind adjustments Glass bottle fabrication Printing machines for food packaging Packaging machines for pre-packed food S.S. White FDA-compliant flexible shafts are resistant to the extreme temperatures found in food industry applications, such as in freezers and ovens. They are resistant to humidity, water, grease, oils, making them easy to clean through either washing or autoclaving. S.S. White’s flexible shaft casings and fittings are all food grade material, and food grade lubricants are available. Flexible shafts can easily be replaced should they fail and are far more affordable than other comparable solutions. S.S. White provides flexible shaft assemblies as part of a custom solution. Every application in which a flexible shaft is used is different, and S.S. White not only manufactures the flexible shafts, but also provides the technical expertise to create bespoke solutions. The food industry requires precise, highly engineered products for a highly regulated environment, which S.S. White delivers consistently. ### About S.S. White Technologies S.S. White Technologies is a world leader in the design, engineering, manufacturing and testing of a variety of flexible shaft products for aerospace, medical, industrial and automotive markets. The majority of commercial and military aircraft platforms in the air today contain at least one S.S. White Technologies flexible rotary shaft, and more than one-half of US manufactured cars and second tier global automotive suppliers rely on S.S. White flexible rotary shafts. The company currently has design, engineering and manufacturing facilities in the United States and the United Kingdom, and manufacturing facilities in India. For more information, visit www.sswhite.net/ Contact: Kristin Nugent McNeil, Gray & Rice, Inc. 617-367-0100 ext. 148 kristin.nugent@mgr1.com

For more variability - the TURBOVAC i/iX family grows Cologne, June 2020 – In June 2020 the vacuum specialist Leybold has expanded its TURBOVAC i/iX series - 90, 250, 350 and 450 - by the sizes 850 i/iX and 950 i/iX to six models. The two new turbomolecular pump variants are characterized by extended, trouble-free operation, longer system life and lower operating costs. They are used in many applications from research and development and analytics to industrial. In other words, especially where a clean and stable high- and ultra- high vacuum is required – such as in coating, heat treatment, analysis, thin-film research and helium recovery. Significantly higher productivity Basically, the new members of the TURBOVAC i/iX family provide significantly improved vacuum performance in a wide range of applications. Especially due to the expansion of the family in the direction of higher pumping speeds and compression values, lower service costs and simple, intuitive operation. In some applications, the integration of the new 850 i/iX and 950 i/iX models will even lead to a significant reduction in the number of pumps and thus in the total life cycle costs. Mountable in any orientation These options are also useful for another reason: Each vacuum application has different installation conditions. This requires flexible installation directions, for example when there is little space for vacuum pumps, as is the case when integrating them into compact, industrial pumping system solutions. Here too, the TURBOVAC i/iX series, with its various models and variants in terms of pumping speeds or compression ratios, is one of the most flexible systems on the market for high-vacuum products and can be mounted in any orientation. Flexible integrated drive electronics Especially in order to promote sales in the industrial and coating market, EthernetIP, EtherCAT and Profinet Anybus options are now added to the existing Profibus, RS232 and RS485 communication modules. They are all available as IP54 versions. The EthernetIP, EtherCAT and Profinet modules have an integrated web server. TURBO.CONTROL i The entire TURBOVAC i/iX series can be controlled and monitored via the TURBO.CONTROL i. The advantage of the controller is that it is equally suitable for integration in high-vacuum applications and compact system solutions. Its application is uncomplicated: It can be operated intuitively via the display and front keys or via a web server interface. The web server allows all pump parameters to be easily monitored and set via PC or mobile device. Cost effective maintenance with very long intervals Last but not least, the maintenance-free and oil-free hybrid bearing concept ensures greater reliability and a longer service life: On the high-vacuum side, the rotor of the turbomolecular pump is guided in a wear-free magnetic bearing, while a ceramic ball bearing lubricated for life is integrated on the backing side, which users can replace themselves on site if necessary. For further information, please contact: Séverine Grimberg Global Communications Coordinator Scientific Vacuum Division Atlas Copco Vacuum Technique Bonner Strasse 498 50968 Cologne Phone: +49 221 347 1211 – Mobile: +49 160 91556457 E-mail: severine.grimberg@vt.atlascopco.com About Leybold Leybold is a part of the Atlas Copco’s Vacuum Technique business area and offers a broad range of advanced vacuum solutions for use in manufacturing and analytical processes, as well as for research purposes. The core capabilities centre on the development of application- and customer-specific systems for the creation of vacuums and extraction of processing gases. Fields of application are secondary metallurgy, heat treatment, automotive industry, coating technologies, solar and thin films such as displays, research & development, analytical instruments, food & packaging, as well as a multitude of other classic industrial processes. About Atlas Copco Great ideas accelerate innovation. At Atlas Copco, we have been turning industrial ideas into business- critical benefits since 1873. By listening to our customers and knowing their needs, we deliver value and innovate with the future in mind. Atlas Copco is based in Stockholm, Sweden with customers in more than 180 countries and about 37 000 employees. Revenues of BSEK 95/ 9 BEUR in 2018. For more information: www.atlascopcogroup.com

EMA’s human medicines committee (CHMP) has recommended granting a marketing authorisation in the European Union for a new Ebola vaccine that provides active immunisation to prevent Ebola virus disease (Zaire ebolavirus species) in individuals aged 1 year and older. Ebola virus disease is a rare but severe and often fatal illness. Between 25% to 90% of the patients who contracted the disease died in past outbreaks. The largest outbreak to date occurred in West Africa in 2014-2016 with more than 11,000 deaths. Currently, the Democratic Republic of Congo (DRC) is fighting an Ebola epidemic. It was declared a public health emergency of international concern by the World Health Organization (WHO) in July 2019. So far, more than 3,400 people in DRC have been infected with the Ebola virus during the ongoing outbreak, and approximately 67% of those infected have died. The recommendation to grant a marketing authorisation for the new vaccine follows the approval of the first Ebola vaccine in November 2019. The new Ebola vaccine consists of two components, Zabdeno (Ad26.ZEBOV) and Mvabea (MVA-BN-Filo). Zabdeno is given first and Mvabea is administered approximately eight weeks later as a booster. This prophylactic 2-dose regimen is therefore not suitable for an outbreak response where immediate protection is necessary. As a precautionary measure, a Zabdeno booster vaccination should be considered for individuals at imminent risk of exposure to Ebola virus, for example healthcare professionals and those living in or visiting areas with an ongoing Ebola virus disease outbreak, who completed the Zabdeno, Mvabea 2-dose primary vaccination regimen more than four months ago. The ability to make the immune system respond to the virus after vaccination with Zabdeno and Mvabea was studied in a total of 3,367 adults, adolescents and children who participated in five clinical studies conducted in Europe, Africa and the USA. These studies demonstrated that the vaccine regimen is safe and could induce an immune response against Ebola virus. Efficacy data in humans has been extrapolated from animal studies. The exact level of protection provided by the vaccine regimen is however unknown. The most common side effects found in participants in the clinical trials were injection-site reactions (pain, warmth and swelling), fatigue, headache, myalgia, arthralgia and chills. Effectiveness data are being collected through an ongoing observational study in DRC. The results of this and other studies must be included in post-marketing safety reports which are continuously reviewed by EMA. As protection against Ebola virus disease is considered to be of major public health interest, Zabdeno and Mvabea were evaluated under EMA's accelerated assessment mechanism, a tool which aims to speed up patients' access to new medicines if there is an unmet medical need. Currently, there are no therapies approved for Ebola. EMA is working together with regulatory authorities around the world to support WHO and to advise on possible pathways for the development, evaluation and approval of medicines and vaccines to fight Ebola. Zabdeno and Mvabea received a positive opinion for marketing authorisations under exceptional circumstances because the applicant was able to demonstrate that it is not possible to conduct a randomised controlled study that might generate comprehensive clinical data on the efficacy of the new Ebola vaccine even after authorisation. This was considered acceptable in light of the ongoing Ebola outbreak and high mortality rates in DRC. The opinion adopted by the CHMP is an intermediary step on Zabdeno and Mvabea’s path to patient access. The CHMP opinion will now be sent to the European Commission for the adoption of a decision on an EU-wide marketing authorisation. Once marketing authorisation has been granted, decisions about price and reimbursement will take place at the level of each Member State taking into account the potential role/use of the new Ebola vaccine in the context of the national health system of that country. Notes The applicant for both Zabdeno and Mvabea is Janssen-Cilag International N.V. A dose of Zabdeno vaccine should be administered as the first vaccination. A dose of Mvabea vaccine should be administered as the second vaccination approximately eight weeks after the first vaccination with Zabdeno. Contact point EMA press office Tel. +31 (0)88 781 8427 E-mail: press@ema.europa.eu Follow us on Twitter @EMA_News

EMA is reminding healthcare professionals to closely monitor patients with COVID-19 who are receiving chloroquine or hydroxychloroquine, given the serious side effects that can result from treatment with these medicines. Both chloroquine and hydroxychloroquine, which are authorised for malaria and certain autoimmune diseases, have been used to treat patients with COVID-19 but their beneficial effects in this patient population are not established. Several observational studies in COVID-19 have reported that chloroquine and hydroxychloroquine are associated with an increased risk of heart problems, a well-known side effect of such treatments, including cardiac arrhythmias and cardiac arrest. When prescribing these medicines, healthcare professionals should take into account pre-existing heart conditions, uncorrected potassium or magnesium imbalance, and concomitant use with medicines that prolong the QT interval as these factors may make patients more prone to heart rhythm disorders. Healthcare professionals should also note that heart rhythm disorders may be more likely or be more severe if chloroquine or hydroxychloroquine are used at higher doses than those recommended for their authorised indications or if they are combined with certain antibiotics such as azithromycin. EMA has previously communicated on these risks. In addition to their effects on the heart, these medicines may cause neuropsychiatric disorders, including agitation, insomnia, confusion, psychosis and suicidal ideation. These medicines are also known to affect the liver, cause neuronal damage that can lead to seizures (fits), and lower blood sugar. In view of the emerging data, some EU countries have suspended or stopped clinical trials investigating chloroquine and hydroxychloroquine in COVID-19 patients. For some trials, including WHO’s large multinational Solidarity trial, enrolment of patients to trial arms with these medicines has been suspended. A preliminary review of the Recovery trial, a large ongoing study on COVID-19 patients, did not identify reasons to suspend or stop the trial. EMA reiterates that while further analyses of available data are being carried out, chloroquine and hydroxychloroquine should only be used in clinical trials for treatment or prophylaxis of COVID-19 or in national emergency use programmes in hospitalised patients under close supervision. It is important that properly designed, randomised clinical trials can be completed, with adjustments as needed, to generate the necessary evidence on benefits and risks of these medicines in COVID-19. Patients who have been prescribed chloroquine or hydroxychloroquine for authorised indications (malaria and certain autoimmune diseases such as rheumatoid arthritis and lupus) should continue to take their medicines as advised by their doctor. Patients who have any questions about their treatment should talk to their doctor or pharmacist. EMA and the national competent authorities are closely monitoring medicines used in the treatment of COVID-19 and will continue communicating and take action as new information emerges. In addition, EMA continues to collaborate and share information with the WHO and international regulators. Patients and healthcare professionals are reminded to report any suspected side effects to their national regulatory authorities. This EMA public health statement has been issued by the COVID-19 EMA pandemic Task Force (COVID-ETF). EMA Press office Tel. +31 (0)88 781 8427 E-mail: press@ema.europa.eu Follow us on Twitter @EMA_News

EVANSVILLE, Ind. – June 3, 2020 – Berry Global Group, Inc. (NYSE: BERY) announced today its collaboration with longtime customer, Mondelēz International to supply packaging containing recycled plastic for Philadelphia, the world’s most popular cream cheese. The package contains plastic material recovered using advanced recycling technology from Berry’s partnership with SABIC, announced earlier this year. Berry prides itself on its ability to provide sustainable, value-added packaging for leading brands around the world and is proud to collaborate with Mondelēz International to improve the sustainability of their packaging. “We are pleased to partner with Mondelēz International in providing packaging made from this advanced recycling technology. By recovering and diverting plastic that would have otherwise been sent to landfill or incineration, we are working towards our common goal of promoting a circular economy,” said Jean-Marc Galvez, President of Berry’s Consumer Packaging International Division. Today’s announcement adds to Berry’s list of initiatives to advance towards a more sustainable future. These initiatives include investment in both mechanical and chemical recycling, the innovative use of recycled material in products, and global commitments to address plastic waste in the environment. Last year, Berry committed that 100 percent of its fast-moving consumer goods packaging would be reusable, recyclable, or compostable by the year 2025. “This is an exciting project which demonstrates our ability to supply a leading worldwide brand with a solution to not only aid in their sustainability commitments, but which also aligns with Berry’s,” said Galvez. About Berry Berry Global Group, Inc. (NYSE: BERY), headquartered in Evansville, Indiana, is committed to its mission of ‘Always Advancing to Protect What’s Important,’ and proudly partners with its customers to provide them with value-added protective solutions that are increasingly light-weighted and easier to recycle or reuse. The Company is a leading global supplier of a broad range of innovative rigid, flexible, and nonwoven products used every day within consumer and industrial end markets. Berry, a Fortune 500 company, has over 48,000 employees and generated $12.6 billion of pro forma net sales in fiscal year 2019, from operations that span over 290 locations on six continents. For additional information, visit Berry’s website at berryglobal.com. Media Contact: Nielsen McAllister Public Relations Limited +44 (0) 1322 293939 info@nmpr.co.uk

Spartanburg, S.C. – Global materials science expert Milliken & Company is once again leveraging its unique capabilities to help produce needed medical personal protective equipment (PPE) amid the COVID-19 pandemic. The current shortage in plastic materials used for protective face shields is leading manufacturers to offer the readily available polypropylene plastic. The material, however, is naturally hazy, so plastic manufacturers are turning to Milliken and the company’s NX® UltraClear™ polypropylene concentrate to produce plastics with clarity levels suitable for healthcare industry face shields. “In this global pandemic, the need for medical PPE continues to rise,” says Halsey M. Cook, president and CEO of Milliken & Company. “We are committed to finding solutions that assist our customers and allow us to join in the fight against COVID-19 wherever we can make a difference.” Milliken has collaborated with a number of plastic manufacturers, from global players to regionally based companies, to evaluate NX UltraClear in this new product application. Impact Plastics is among the U.S. companies using NX UltraClear concentrates to make polypropylene clear for use in face shields. Mezger in Germany is also employing NX UltraClear concentrates to produce polypropylene sheet suitable for use in face shields. Medical face shields made with NX UltraClear polypropylene are now in the market and being used by front-line workers. For editorial enquiries, please contact Betsy Sikma Milliken Chemical +1 864 909 7908 betsy.sikma@milliken.com Mollie Williams M. Williams Communications Group +1 864 419 6204 mollie@mwilliamscg.com

Mondi's plant in Korneuburg, Austria ramps up production to supply packaging for the new to market SARS-CoV-2 test cartridge by QIAGEN Mondi will produce a high-barrier triplex laminate which will provide protection for the test kits which require limited exposure to light and oxygen to remain effective 02 June 2020 – Mondi, a leading global packaging and paper group, is committed to playing its part in the supply of essential products during the COVID-19 outbreak and has recently developed packaging for QIAGEN's SARS-CoV-2 coronavirus test kit. QIAGEN is a leading global provider of molecular Sample to Insight solutions. The company recently launched a syndromic test cartridge kit for the QIAstat-Dx Analyser System that can identify the SARS-CoV-2 coronavirus within an hour. Designed for use in hospitals, clinics and laboratories, the company’s new QIAstat-Dx syndromic testing platform comes in the form of a compact, modular, table-top device into which multi-chamber cartridges containing test samples are inserted for analysis. During times like these, flexibility in production is key to help support essential packaging needs in the medical industry. “Given that timely testing is a critical component of mitigating the spread of the pandemic, we stand ready to assist the medical community in any way we can. At Mondi Korneuburg, we adjusted our production planning in order to meet the increase in demand to support QIAGEN,” explains Eveline Wagner, Managing Director of Mondi Korneuburg. Mondi has an ongoing relationship with QIAGEN and is providing packaging for the test cartridges using a customised design. The white, unprinted, multilayer pouches consist of a polyester/aluminium/polyethylene (PET/Alu/PE) construction to provide the necessary protection from light and moisture so that the test kits are not compromised before they are used. “We worked closely with QIAGEN to understand how best to ensure test kits are packaged safely. We are now ready to scale up production of this product and meet the new demands,” says Emilio Vidri, Sales Director Europe, Mondi Consumer Flexibles. /ends About Mondi Mondi is a global leader in packaging and paper, contributing to a better world by making innovative, packaging and paper solutions that are sustainable by design. Our business is fully integrated across the value chain – from managing forests and producing pulp, paper and plastic films, to developing and manufacturing effective industrial and consumer packaging solutions. Sustainability is at the centre of our strategy and intrinsic in the way we do business. We lead the industry with our customer- centric approach, EcoSolutions, where we ask the right questions to find the most sustainable solution. In 2019, Mondi had revenues of €7.27 billion and underlying EBITDA of €1.66 billion. Mondi has a premium listing on the London Stock Exchange (MNDI), and a secondary listing on the JSE Limited (MNP). Mondi is a FTSE 100 constituent, and has been included in the FTSE4Good Index Series since 2008 and the FTSE/JSE Responsible Investment Index Series since 2007. www.mondigroup.com Contact: Judith Wronn Senior Communication Manager, Flexible Packaging & Engineered Materials Tel: +49 151 1771 4692 Email: Judith.Wronn@mondigroup.com Josina van der Velden EMG Tel: +31 164 317 014 Email: jvandervelden@emg-marcom.com

UPM Raflatac and YG Branding and Design Experts are proud to present the first global virtual expo for wine and spirits, focusing on the packaging value chain, on 9-10 June 2020. The fair is organized in collaboration with more than a dozen other partners from around in the world in the wine and spirits packaging value chain that cover industries such as label printing, foil stamping and glass bottle production, to mention a few. This virtual event consists of panel discussions and webinars that will share the latest trends and industry insights as well as connect customers, suppliers and colleagues across the industry and the globe. We all need to #MoveOn and so do our brands “The world is changing in a way we cannot yet estimate. But we are sure that the virtual world is becoming a natural method of contact between clients and suppliers. Together with our partners we are building a virtual platform that delivers live experiences, valuable content and new connections to industry members around the world. In these webinars we will cover topical themes such as sustainability, packaging innovation & education, as well as design and trends,” says Stefano Pistoni, Manager, Global Business Development, Wine & Spirits, UPM Raflatac. The expo is open for everyone interested in the wine and spirits industry. Participants will have an opportunity to visit interesting virtual stands hosted by some of the most prestigious providers in the global industry. In addition, visitors will have access to several webinar sessions and panel discussions with live engagement. "This event co-organized by UPM Raflatac and YG Branding & Design Experts is a great example of what the world needs once this crisis is over: collaboration and co-creation to Move On," says Sebastian Yáñez, Director, YG Branding & Design Experts. UPM Raflatac UPM Raflatac is leading in sustainable labeling through our innovative self-adhesive label materials and services. We offer high-quality paper and film label stock for branding and promotion, informational labels, and labels with functionality. We operate a global network of factories, distribution terminals and sales offices. Our company employs around 3,000 people and made sales of EUR 1.6 billion (USD 1.8 billion) in 2019. UPM Raflatac is part of UPM. Find out how we are labeling a smarter future beyond fossils at www.upmraflatac.com. Follow UPM Raflatac on Twitter | LinkedIn | Facebook | YouTube | Instagram UPM We deliver renewable and responsible solutions and innovate for a future beyond fossils across six business areas: UPM Biorefining, UPM Energy, UPM Raflatac, UPM Specialty Papers, UPM Communication Papers and UPM Plywood. As the industry leader in responsibility we are committed to the UN Business Ambition for 1.5°C and the science-based targets to mitigate climate change. We employ 18,700 people worldwide and our annual sales are approximately EUR 10.2 billion. Our shares are listed on Nasdaq Helsinki Ltd. UPM Biofore – Beyond fossils. www.upm.com For further information please contact: Stefano Pistoni, Manager, Global Business Development, Wine & Spirits, UPM Raflatac, stefano.pistoni@upmraflatac.com UPM, Media Relations Mon-Fri 9:00-16:00 EET tel. +358 40 588 3284 media@upm.com Follow UPM on Twitter | LinkedIn | Facebook | YouTube | Instagram | #UPM #biofore #beyondfossils

Many brands and retailers could reduce the climate impact of their packaging up to 50 percent and avoid thousands of tonnes of carbon dioxide being emitted to air. The results is based on a large number of life cycle assessments performed by BillerudKorsnäs in a new tool that evaluates the environmental impact of different packaging solutions. The digital tool has received a warm welcome by customers and brand owners in their pursuit of reducing carbon emissions. Global demand for packaging is rising with sustainability as a strong driver, which means future packaging will need to be designed so that it does not impact our climate. - There is a knowledge gap on the market, says Johan Tegell, Business Development Director at BillerudKorsnäs. Companies don’t realise how much they can reduce their carbon and fresh water footprint from packaging. It’s about optimising the packaging to the supply chain and choosing suitable raw materials. Normally just small adjustments are needed to get great environmental savings. This was the reason why we introduced a life cycle assessment tool, to provide our customers with environmental insights about their packaging. Most customers are surprised when they see the results and realise the potential savings. Life cycle assessment is a technique used to assess the environmental impact associated with all the stages of a product's life, from the extraction of raw materials through to processing, manufacturing, transportation and end-of-life treatment. Traditionally, performing one single life cycle assessment could take months of work due to the large amount of data that needs to be collected from the value chain. The recently introduced digital tool contains an extensive database on different packaging materials, including data from BillerudKorsnäs’ own production. By selecting a number of parameters related to the packaging, such as material, size, production location, transport, and disposal method, it will show the total life cycle impact for carbon dioxide emissions and water consumption. At BillerudKorsnäs, the tool is mainly used to improve supply chain efficiency and environmental performance for customers with production in Asia. Customers can then use the information in their environmental communication and sustainability reporting. The apparel company LPP, that has over 1,700 stores across the world, was one of the pioneers to try the new life cycle assessment tool together with BillerudKorsnäs. - Sustainability is the most important topic in today’s world and we at LPP are very serious about taking care of the future. The cooperation with BillerudKorsnäs and the use of the life cycle assessment tool enabled LPP not only to understand but to practically reduce the emission of CO2. The implementation of BillerudKorsnäs’ packaging solutions supported LPP’s internal CO2 goals, says Monika Kotwicka, Manager Purchasing Processes at LPP. During the year, BillerudKorsnäs will further develop the tool to include more data points on different materials. The tool is 3rd party reviewed and used on all projects within the Business Unit Managed Packaging. BillerudKorsnäs provides packaging materials and solutions that challenge conventional packaging for a sustainable future. We are a world-leading provider of primary fibre based packaging materials and have customers in over 100 countries. The company has 8 production units in Sweden, Finland and the UK and about 4300 employees in over 13 countries. BillerudKorsnäs has an annual turnover of about SEK 22 billion and is listed on Nasdaq Stockholm. www.billerudkorsnas.com For further information, please contact: Johan Tegell, Business Development Director, Managed Packaging, +46855333725, johan.tegell@billerudkorsnas.com Louise Wileen Bjarke, Head of Press, +46722103514, louise.wileenbjarke@billerudkorsnas.com